Reply to “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence”

Annals of Neurology 2026 Open access

Read full text
Authors: Gabriel Cerono, Bruce A C Cree, Stephen L. Hauser, Sergio E. Baranzini
DOI: 10.1002/ana.78133
Cited by: 1
References: 2

Fields of Study & Subjects

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Annals of Neurology
Publisher
Wiley
Volume
99
Issue
2
Pages
553–553
Publication date
1 February 2026
Language
EN